| 1. |
- DeFelipe, Irene, et al.
(författare)
-
Reassessing the lithosphere : SeisDARE, an open-access seismic data repository
- 2021
-
Ingår i: Earth System Science Data. - : Copernicus Publications. - 1866-3508 .- 1866-3516. ; 13:3, s. 1053-1071
-
Tidskriftsartikel (refereegranskat)abstract
- Seismic reflection data (normal incidence and wide angle) are unique assets for solid Earth sciences as they provide critical information about the physical properties and structure of the lithosphere as well as about the shallow subsurface for exploration purposes. The resolution of these seismic data is highly appreciated; however they are logistically complex and expensive to acquire, and their geographical coverage is limited. Therefore, it is essential to make the most of the data that have already been acquired. The collation and dissemination of seismic open-access data are then key to promote accurate and innovative research and to enhance new interpretations of legacy data. This work presents the Seismic DAta REpository (SeisDARE), which is, to our knowledge, one of the first comprehensive open-access online databases that stores seismic data registered with a permanent identifier (DOI). The datasets included here are openly accessible online and guarantee the FAIR (findable, accessible, interoperable, reusable) principles of data management, granting the inclusion of each dataset in a statistics referencing database so its impact can be measured. SeisDARE includes seismic data acquired in the last 4 decades in the Iberian Peninsula and Morocco. These areas have attracted the attention of international researchers in the fields of geology and geophysics due to the exceptional outcrops of the Variscan and Alpine orogens and wide foreland basins, the crustal structure of the offshore margins that resulted from a complex plate kinematic evolution, and the vast quantities of natural resources contained within. This database has been built thanks to a network of national and international institutions, promoting a multidisciplinary research and is open for international data exchange and collaborations. As part of this international collaboration, and as a model for inclusion of other global seismic datasets, SeisDARE also hosts seismic data acquired in Hardeman County, Texas (USA), within the COCORP project (Consortium for Continental Reflection Profiling). SeisDARE aims to make easily accessible old and recently acquired seismic data and to establish a framework for future seismic data management plans. SeisDARE is freely available at https://digital.csic.es/handle/10261/101879 (a detailed list of the datasets can be found in Table 1), bringing endless research and teaching opportunities to the scientific, industrial, and educational communities.
|
|
| 2. |
- Gutierrez-Gutierrez, Belen, et al.
(författare)
-
Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing Enterobacterales in Kidney Transplant Recipients
- 2021
-
Ingår i: Antimicrobial Agents and Chemotherapy. - : American Society for Microbiology. - 0066-4804 .- 1098-6596. ; 65:11
-
Tidskriftsartikel (refereegranskat)abstract
- There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT, NCT02852902). The association between targeted therapy with ertapenem versus meropenem and clinical cure at day 14 (the principal outcome) was studied by logistic regression. Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 patients were included; only 1 patient (treated with meropenem) in the cohort died. Clinical cure at day 14 was reached in 45/100 (45%) and 51/101 (50.5%) of patients treated with ertapenem and meropenem, respectively (adjusted OR 1.29; 95% CI 0.51 to 3.22; P = 0.76); the propensity score-matched cohort included 55 pairs (adjusted OR for clinical cure at day 14, 1.18; 95% CI 0.43 to 3.29; P = 0.74). In this cohort, the proportion of cases treated with ertapenem with better DOOR than with meropenem was 49.7% (95% CI, 40.4 to 59.1%) when hospital stay was considered. It ranged from 59 to 67% in different scenarios of a modified (weights-based) DOOR sensitivity analysis when potential ecological advantage or cost was considered in addition to outcome. In conclusion, targeted therapy with ertapenem appears as effective as meropenem to treat nonsevere B-UTI due to ESBL-E in KT recipients and may have some advantages.
|
|
| 3. |
- Pierrotti, Ligia C., et al.
(författare)
-
Efficacy of beta-lactam/beta-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project)
- 2021
-
Ingår i: Transplant Infectious Disease. - : John Wiley & Sons. - 1398-2273 .- 1399-3062. ; 23:3
-
Tidskriftsartikel (refereegranskat)abstract
- Background Whether active therapy with beta-lactam/beta-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant recipients (KTRs) remains unclear. Methods We retrospectively evaluated 306 KTR admitted to 30 centers from January 2014 to October 2016. Therapeutic failure (lack of cure or clinical improvement and/or death from any cause) at days 7 and 30 from ESBL-E BSI onset was the primary and secondary study outcomes, respectively. Results Therapeutic failure at days 7 and 30 occurred in 8.2% (25/306) and 13.4% (41/306) of patients. Hospital-acquired BSI (adjusted OR [aOR]: 4.10; 95% confidence interval [CI]: 1.50-11.20) and Pitt score (aOR: 1.47; 95% CI: 1.21-1.77) were independently associated with therapeutic failure at day 7. Age-adjusted Charlson Index (aOR: 1.25; 95% CI: 1.05-1.48), Pitt score (aOR: 1.72; 95% CI: 1.35-2.17), and lymphocyte count <= 500 cells/mu L at presentation (aOR: 3.16; 95% CI: 1.42-7.06) predicted therapeutic failure at day 30. Carbapenem monotherapy (68.6%, primarily meropenem) was the most frequent active therapy, followed by BLBLI monotherapy (10.8%, mostly piperacillin-tazobactam). Propensity score (PS)-adjusted models revealed no significant impact of the choice of active therapy (carbapenem-containing vs any other regimen, BLBLI- vs carbapenem-based monotherapy) within the first 72 hours on any of the study outcomes. Conclusions Our data suggest that active therapy based on BLBLI may be as effective as carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. Potential residual confounding and unpowered sample size cannot be excluded (ClinicalTrials.gov identifier: NCT02852902).
|
|
